Plasmodium vivax malaria vaccines: Why are we where we are?

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 12, 2013, Pages 2558-2565

  Reyes Sandoval, Arturo ^a   Bachmann, Martin F ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Clinical trials; Human trials; Malaria; Plasmodium vivax; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; CIRCUMSPOROZOITE PROTEIN; FREUND ADJUVANT; MALARIA VACCINE; PEPTIDE VACCINE; PVS25H PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR; VIVAX 1; VIVAX MALARIA PROTEIN 1;

ANOPHELES; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASEXUAL REPRODUCTION; CELLULAR IMMUNITY; DISEASE MODEL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA NODOSUM; HUMAN; IMMUNOGENICITY; MALARIA FALCIPARUM; MORTALITY; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM VIVAX MALARIA; SPOROZOITE; UNSPECIFIED SIDE EFFECT; VECTOR CONTROL;

CLINICAL TRIALS; HUMAN TRIALS; MALARIA; PLASMODIUM VIVAX; VACCINE;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HUMANS; MALARIA VACCINES; MALARIA, VIVAX; PLASMODIUM VIVAX;

EID: 85047688575     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26157     Document Type: Article

References (59)

1. Guerra CA, Howes RE, Patil A.P., Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh B.H., Elyazar IR, et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis 2010; 4: e774; PMID: 20689816; http://dx.doi.org/10.1371/jour-nal.pntd. 0000774
2. Hay SI, Okiro EA, Gething P.W., Patil AP, Tatem AJ, Guerra C.A., Snow RW. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med 2010; 7: e1000290; PMID: 20563310; http://dx.doi.org/10.1371/journal. pmed.1000290
3. Price RN, Tjitra E, Guerra C.A., Yeung S., White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007; 77(Suppl): 79-87; PMID: 18165478
4. Gething PW, Elyazar IR, Moyes C.L., Smith DL, Battle KE, Guerra CA, Patil A.P., Tatem AJ, Howes RE, Myers MF, George D.B., Horby P., Wertheim HF, Price RN, Müeller I, Baird J.K., Hay SI. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012; 6: e1814.
5. Gething PW, Patil AP, Smith D.L., Guerra CA, Elyazar IR, Johnston GL, Tatem A.J., Hay SI. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 2011; 10: 378; PMID: 22185615; http://dx.doi.org/10.1186/1475- 2875-10-378
6. PATH. 2011. Staying the course? Malaria Research and Development in a Time of Economic Uncerainty. Seattle. PATH. http://www.malariavaccine.org/files/ RD-report-June2011.pdf, PATH, Seattle.
7. Tjitra E, Anstey NM, Sugiarto P, Warikar N., Kenangalem E, Karyana M, Lampah D.A., Price RN. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: A prospective study in Papua, Indon (Pubitemid 351919110)
8. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 2009; 22: 430-5; PMID: 19571748; http://dx.doi.org/10.1097/QCO. 0b013e32832f14c1
9. Roberts L, Enserink M. Malaria. Did they really say... eradication? Science 2007; 318: 1544-5; PMID: 18063766; http://dx.doi.org/10.1126/science. 318.5856.1544 (Pubitemid 350233641)
10. Bass CC, Johns FM. The Cultivation of Malarial Plasmodia (Plasmodium Vivax and Plasmodium Falciparum) in Vitro. J Exp Med 1912; 16: 567-79; PMID: 19867597; http://dx.doi.org/10.1084/jem.16.4.567
11. Noulin F, Borlon C, Van Den Abbeele J, D'Alessandro U, Erhart A. 1912-2012: A century of research on Plasmodium vivax in vitro culture. Trends Parasitol 2013; 29: 286-94; PMID: 23623759; http://dx.doi.org/10.1016/j.pt.2013. 03.012
12. Jordan-Villegas A., Zapata JC, Perdomo A.B., Quintero GE, Solarte Y, Arévalo-Herrera M, Herrera S. Aotus lemurinus griseimembra monkeys: A suitable model for Plasmodium vivax sporozoite infection. Am J Trop Med Hyg 2005; 73(Suppl): 10-5; PMID: 16291761 (Pubitemid 41688443)
13. Douglas RG, Sadoff J, Samant V. 2008. The Vaccine Industry. Philadelphia: Saunders.
14. Moran M, Ropars A, Guzman J., Garrison C. 2005. The new landscape of neglected disease drug development., ed. TW Trust. London: The Wellcome Trust.
15. Galinski MR, Barnwell JW. Plasmodium vivax: who cares? Malar J 2008; 7(Suppl 1): S9; PMID: 19091043; http://dx.doi.org/10.1186/1475-2875-7-S1-S9
16. Valencia SH, Rodríguez DC, Acero D.L., Ocampo V., Arévalo-Herrera M. Platform for Plasmodium vivax vaccine discovery and development. Mem Inst Oswaldo Cruz 2011; 106(Suppl 1): 179-92; PMID: 21881773; http://dx.doi.org/10.1590/S0074-02762011000900023
17. Agnandji ST, Lell B, Fernandes J.F., Abossolo BP, Methogo BG, Kabwende AL, Adegnika A.A., Mordmüller B, Issifou S., Kremsner PG, et al.; RTS, S Clinical Trials Partnership. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367: 2284-95; PMID: 23136909; http://dx.doi.org/10.1056/NEJMoa1208394
18. Nussenzweig RS, Vanderberg J, Most H., Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 1967; 216: 160-2; PMID: 6057225; http://dx.doi.org/10.1038/216160a0
19. Sinden RE. A biologist's perspective on malaria vaccine development. Hum Vaccin 2010; 6: 3-11; PMID: 19946205; http://dx.doi.org/10.4161/hv.6.1.9604
20. Reyes-Sandoval A., Berthoud T, Alder N., Siani L, Gilbert SC, Nicosia A, Colloca S., Cortese R, Hill AV. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010; 78: 145-53; PMID: 19858306; http://dx.doi.org/10.1128/IAI.00740-09
21. Reyes-Sandoval A., Sridhar S, Berthoud T., Moore AC, Harty JT, Gilbert SC, Gao G, Ertl H.C., Wilson JC, Hill AV. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 2008; 38: 732-41; PMID: 18266272; http://dx.doi.org/10.1002/eji. 200737672
22. Reyes-Sandoval A., Wyllie DH, Bauza K, Milicic A., Forbes EK, Rollier CS, Hill AV. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 2011; 187: 1347-57; PMID: 21715686; http://dx.doi.org/10.4049/jimmunol. 1100302
23. Yoshida N, Potocnjak P, Nussenzweig V., Nussenzweig RS. Biosynthesis of Pb44, the protective antigen of sporozoites of Plasmodium berghei. J Exp Med 1981; 154: 1225-36; PMID: 7026723; http://dx.doi.org/10.1084/jem.154.4.1225 (Pubitemid 11023110)
24. Tewari R, Spaccapelo R, Bistoni F., Holder AA, Crisanti A. Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity. J Biol Chem 2002; 277: 47613-8; PMID: 12244064; http://dx.doi.org/10.1074/jbc.M208453200 (Pubitemid 36159282)
25. Potocnjak P, Yoshida N, Nussenzweig R.S., Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med 1980; 151: 1504-13; PMID: 6991628; http://dx.doi.org/10.1084/jem.151.6.1504 (Pubitemid 10062946)
26. Warburg A, Touray M, Krettli A.U., Miller LH. Plasmodium gallinaceum: antibodies to circumspo-rozoite protein prevent sporozoites from invading the salivary glands of Aedes aegypti. Exp Parasitol 1992; 75: 303-7; PMID: 1426132; http://dx.doi.org/10.1016/0014-4894(92)90215-V
27. Lim CS, Tazi L, Ayala FJ. Plasmodium vivax: recent world expansion and genetic identity to Plasmodium simium. Proc Natl Acad Sci USA 2005; 102: 15523-8; PMID: 16227436; http://dx.doi.org/10.1073/pnas.0507413102 (Pubitemid 41528090)
28. Barr PJ, Gibson HL, Enea V, Arnot D.E., Hollingdale MR, Nussenzweig V. Expression in yeast of a Plasmodium vivax antigen of potential use in a human malaria vaccine. J Exp Med 1987; 165: 1160-71; PMID: 3549959; http://dx.doi.org/10.1084/jem.165.4.1160 (Pubitemid 17064511)
29. Collins WE, Nussenzweig RS, Ballou W.R., Ruebush TK 2nd, Nardin EH, Chulay J.D., Majarian WR, Young JF, Wasserman GF, Bathurst I, et al. Immunization of Saimiri sciureus boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium vivax. Am J Trop Med Hyg 1989; 40: 455-64; PMID: 2658634 (Pubitemid 19148472)
30. Herrington DA, Nardin EH, Losonsky G, Bathurst I.C., Barr PJ, Hollingdale MR, Edelman R, Levine MM. Safety and immunogenicity of a recombinant sporozoite malaria vaccine against Plasmodium vivax. Am J Trop Med Hyg 1991; 45: 695-701; PMID: 1763796
31. Corradin G, Céspedes N, Verdini A., Kajava AV, Arévalo-Herrera M, Herrera S. Malaria vaccine development using synthetic peptides as a technical platform. Adv Immunol 2012; 114: 107-49; PMID: 22449780; http://dx.doi.org/10.1016/B978-0-12-396548-6.00005-6
32. Herrera S, Bonelo A, Perlaza B.L., Valencia AZ, Cifuentes C, Hurtado S, Quintero G., López JA, Corradin G., Arévalo-Herrera M. Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circum-sporozoite protein. Int J Parasitol 2004; 34: 1535-46; PMID: 15582530; http://dx.doi.org/10.1016/j.ijpara.2004.10.009
33. Herrera S, Bonelo A, Perlaza B.L., Fernández OL, Victoria L., Lenis AM, Soto L, Hurtado H, Acuña LM, Vélez JD, et al. Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 2005; 73(Suppl): 3-9; PMID: 16291760 (Pubitemid 41688442)
34. Yadava A, Sattabongkot J, Washington M.A., Ware LA, Majam V, Zheng H, Kumar S., Ockenhouse CF. A novel chimeric Plasmodium vivax circumsporozo-ite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun 2007; 75: 1177-85; PMID: 17158893; http://dx.doi.org/10.1128/IAI.01667-06 (Pubitemid 46385808)
35. rd, Washington MA, Wood C.L., Ware LA, Ockenhouse CF, Yadava A. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax. Vaccine 2009; 27: 1448-53; PMID: 19138714; http://dx.doi.org/10.1016/j.vaccine.2008.12.027
36. Lumsden JM, Pichyangkul S, Srichairatanakul U., Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S., Klein J, Bertholet S, Vedvick T.S., Reed SG, et al. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect Immun 2011; 79: 3492-500; PMID: 21690242; http://dx.doi.org/10.1128/IAI.05257-11
37. Lumsden JM, Nurmukhambetova S, Klein J.H., Sattabongkot J., Bennett JW, Bertholet S, Fox CB, Reed S.G., Ockenhouse CF, Howard RF, et al. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice. Vaccine 2012; 30: 3311-9; PMID: 22425788; http://dx.doi.org/10.1016/j.vaccine.2012.03.004
38. Moon JJ, Suh H, Polhemus M.E., Ockenhouse CF, Yadava A, Irvine DJ. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS One 2012; 7: e31472; PMID: 22328935; http://dx.doi.org/10.1371/journal.pone.0031472
39. Study of VMP001 and AS01B in Healthy MalariaNaive Adults.
40. Zakeri S, Razavi S, Djadid ND. Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran. Acta Trop 2009; 109: 176-80; PMID: 18950597; http://dx.doi.org/10.1016/j.actatropica.2008.09.012
41. Hill AV. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 2011; 366: 2806-14; PMID: 21893544; http://dx.doi.org/10.1098/rstb.2011.0091
42. malERA Consultative Group on Vaccines. A research agenda for malaria eradication: vaccines. PLoS Med 2011; 8: e1000398; PMID: 21311586; http://dx.doi.org/10.1371/journal.pmed.1000398
43. Feachem RG, Phillips AA, Hwang J, Cotter C., Wielgosz B, Greenwood BM, Sabot O, Rodriguez M.H., Abeyasinghe RR, Ghebreyesus TA, et al. Shrinking the malaria map: progress and prospects. Lancet 2010; 376: 1566-78; PMID: 21035842; http://dx.doi.org/10.1016/S0140-6736(10)61270-6
44. Greenwood BM, Targett GA. Malaria vaccines and the new malaria agenda. Clin Microbiol Infect 2011; 17: 1600-7; PMID: 21883665; http://dx.doi.org/10. 1111/j.1469-0691.2011.03612.x
45. Tomas AM, Margos G, Dimopoulos G., van Lin LH, de Koning-Ward TF, Sinha R, Lupetti P, Beetsma AL, Rodriguez MC, Karras M, et al. P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions. EMBO J 2001; 20: 3975-83; PMID: 11483501; http://dx.doi.org/10.1093/emboj/20.15. 3975 (Pubitemid 32751814)
46. Wu Y, Ellis RD, Shaffer D, Fontes E., Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K., Miles AP, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008; 3: e2636; PMID: 18612426; http://dx.doi.org/10.1371/jour-nal.pone.0002636
47. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y., Miura K, Long CA, Lambert L, Miles A.P., Wang J., et al. Phase 1 vaccine trial of Pvs25H: A transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005; 23: 3131-8; PMID: 15837212; http://dx.doi.org/10.1016/j.vaccine.2004.12.019
48. Hisaeda H, Stowers AW, Tsuboi T, Collins W.E., Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 2000; 68: 6618-23; PMID: 11083773; http://dx.doi.org/10.1128/IAI.68.12. 6618-6623.2000 (Pubitemid 32463362)
49. Sattabongkot J, Tsuboi T, Hisaeda H., Tachibana M, Suwanabun N, Rungruang T., Cao YM, Stowers AW, Sirichaisinthop J, Coleman R.E., et al. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. Am J Trop Med Hyg 2003; 69: 536-41; PMID: 14695092 (Pubitemid 38248256)
50. Galinski MR, Medina CC, Ingravallo P, Barnwell JW. A reticulocyte-binding protein complex of Plasmodium vivax merozoites. Cell 1992; 69: 1213-26; PMID: 1617731; http://dx.doi.org/10.1016/0092-8674(92)90642-P
51. Boyd M, Stratman-Thomas, W, Muench, H The occurrence of gametocytes of Plasmodium vivax during the primary attack. Am J Trop Med Hyg 1936; s1-16: 133-8
52. Galinski MR, Meyer EV, Barnwell JW. Plasmodium vivax: modern strategies to study a persistent parasite's life cycle. Adv Parasitol 2013; 81: 1-26; PMID: 23384620; http://dx.doi.org/10.1016/B978-0-12-407826-0.00001-1
53. Chitnis CE, Sharma A. Targeting the Plasmodium vivax Duffy-binding protein. Trends Parasitol 2008; 24: 29-34; PMID: 18023618; http://dx.doi.org/10. 1016/j.pt.2007.10.004
54. Ménard D., Barnadas C, Bouchier C., Henry-Halldin C, Gray LR, Ratsimbasoa A, Thonier V., Carod JF, Domarle O, Colin Y, et al. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci USA 2010; 107: 5967-71; PMID: 20231434; http://dx.doi.org/10.1073/ pnas.0912496107
55. Bachmann MF, Jennings GT. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10: 787-96; PMID: 20948547; http://dx.doi.org/10.1038/nri2868
56. Bachmann MF, Rohrer UH, Kündig TM, Bürki K, Hengartner H., Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science 1993; 262: 1448-51; PMID: 8248784; http://dx.doi.org/10.1126/science. 8248784 (Pubitemid 24035067)
57. Capone S, Reyes-Sandoval A, Naddeo M., Siani L, Ammendola V, Rollier C.S., Nicosia A., Colloca S, Cortese R, Folgori A., et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 2010; 29: 256-65; PMID: 21029806; http://dx.doi.org/10.1016/j.vaccine.2010.10.041
58. O'Hara G.A., Duncan CJ, Ewer K.J., Collins KA, Elias SC, Halstead FD, Goodman A.L., Edwards NJ, Reyes-Sandoval A, Bird P, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: A potent new vaccine vector. J Infect Dis 2012; 205: 772-81; PMID: 22275401; http://dx.doi.org/10.1093/infdis/jir850
59. Moram M, Ropars A, Guzman J., Diaz J, Garrison C. 2005. The new landscape of neglected disease drug development. London: The Wellcome Trust.